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Background: Polyneuropathy organomegaly endocrinopathy M-protein skin changes (POEMS) syndrome is a rare
cause of polyneuropathy. Calciphylaxis, a severe disease leading to necrotic ulcers of the skin, is associated with
POEMS syndrome and also with renal disease. This case report describes a patient with POEMS syndrome plus
primary focal segmental glomerulosclerosis.
Case presentation: A 27-year-old Caucasian woman with chronic renal insufficiency due to focal segmental
glomerulosclerosis and calciphylaxis presented to our institution with polyneuropathy and encephalopathy. An
extensive diagnostic workup revealed POEMS syndrome. Serum concentrations of vascular endothelial growth
factor (VEGF) were highly elevated, consistent with POEMS syndrome.
Conclusion: To our knowledge, this is the first report of a patient with POEMS syndrome and primary focal
segmental glomerulosclerosis. The combination of POEMS syndrome, calciphylaxis and primary focal segmental
glomerulosclerosis may be coincidental, suggesting the need for additional studies to confirm or exclude this
association. VEGF may be an important pathogenetic link, suggesting that treatment with antiangiogenic agents may
improve patient outcomes.
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POEMS (polyneuropathy, organomegaly, endocrinopa-
thy, M-protein, skin changes) syndrome is a rare multi-
system disease caused by a monoclonal gammopathy.
POEMS syndrome might be a risk factor for calciphy-
laxis by upregulating vascular endothelial growth factor
(VEGF) and proinflammatory cytokines [1]. Calciphy-
laxis is characterized by calcification of the arterioles,
resulting in rapidly progressive necrotic ulcers of the
skin and subcutis. Calciphylaxis is frequently associated
with renal failure. One-year mortality rates are high, with
death mostly due to sepsis. This report describes a patient
with the combination of POEMS syndrome, calciphylaxis* Correspondence: dorothee.heck@uniklinik-freiburg.de
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and discusses a possible pathogenetic link.Case presentation
A 27-year-old Caucasian woman recently diagnosed with
chronic renal failure, pulmonary embolism and calciphy-
laxis was admitted to our hospital due to weakness and
mental alterations. Two months earlier, this patient had
presented with a severe nephrotic syndrome, with a
renal biopsy revealing a primary FSGS with typical al-
most complete podocyte foot process fusion on electron
microscopy. Calciphylactic skin changes were confirmed
by deep skin biopsies, which showed calcifying pannicu-
litis. The patient was started on daily hemodialysis to
treat her calciphylaxis and owing to a poor response of
FSGS to steroids. She was also administered sodium
thiosulfate thrice weekly, along with careful wound care
and lymphatic drainage.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lymphedema, deep necrotic ulcers on the lower legs and
generalized pitting edema (Figure 1). Peripheral pulses
were intact. Neurological examination revealed clouding
of consciousness and psychomotor slowing. Inspection
of her hands showed noticeable atrophy of the interos-
seal and thenar muscles. She was able to hold her arms
over her head but could not lift her legs due to pain and
weakness. The reflexes of her upper extremities were
symmetrically normal. Owing to hyperalgesia of the
limbs, however, she did not tolerate a knee jerk. An oph-
thalmologic examination showed physiological findings.
Electrophysiological testing, including nerve conduc-
tion tests and an electromyogram, revealed an axonal-
demyelinating polyneuropathy. Electroencephalography
showed a mild encephalopathy, but no epileptiform
activity.
Magnetic resonance imaging (MRI) of the brain showed
fine calcifications of the basal ganglia and the dentate nu-
clei, indicating strio-pallido-dentate calcinosis. Bilateral
chronic lesions in the putamen and in the head of the
caudate nucleus were also observed. There was no evi-
dence of mitochondrial encephalopathy, because lactate
was not detectable on magnetic resonance spectroscopy
(Figure 2).
Laboratory results (Table 1) showed anemia and
leukocytosis. C-reactive protein concentration was highly
elevated. There was marked hypoalbuminemia and
nephrotic-range proteinuria, with a urinary protein/
creatinine ratio of 19.9 g/g. Creatinine kinase activity was
normal, but thyroid function tests revealed hypothyroidism.A
Figure 1 Calciphylaxis-induced skin changes on the right lower leg. C
plaque-like lesion and a small ulcer (A) and progressed within two weeks tThe patient experienced one episode of hypoglycemia
of 50 mg/dL. Secondary hyperparathyroidism was detected,
consistent with chronic renal insufficiency. Serum immu-
nofixation revealed a monoclonal gammopathy (immuno-
globulin G lambda). Serum VEGF levels were highly
significantly elevated (1.329 ± 80 pg/mL). Extensive im-
munologic testing was unremarkable. The cerebrospinal
fluid showed a mild blood–brain barrier disruption.
Histological and cytological examination of the bone
marrow showed a proliferation of plasma cells, consistent
with a monoclonal gammopathy of undetermined signifi-
cance (MGUS). Additional histological examinations of the
renal biopsy did not provide any evidence for renal involve-
ment in MGUS. Muscle biopsy revealed type II fiber atro-
phy. There was no evidence of muscular inflammation,
metabolic myopathy or a mitochondrial disorder.
POEMS syndrome was diagnosed based on polyneur-
opathy, monoclonal plasma cell disorder with IgG lambda,
elevated serum VEGF, extravascular volume overload,
endocrinopathy and skin changes, consistent with pro-
posed diagnostic criteria [2].
The patient was treated with cyclophosphamide, dexa-
methasone, rituximab and bortezomib. Calciphylactic skin
changes and hyperalgesia ameliorated gradually. Neuro-
cognitive abilities improved slightly and mobilization was
possible with the aid of a walker, but the patient still re-
quires care.
Conclusions
Neurological manifestations in calciphylaxis are rare,
but could explain myopathy and encephalopathy in ourB
alciphylaxis-induced skin changes presented initially as a violaceous
o a deep necrotic ulcer with eschar (B).
Table 1 Laboratory results
Variable Value (normal range)
Hemoglobin, g/dL 7.1 (12–18)
White blood cell count, × 103/μL 15.99 (4.3-10)
Platelet count, × 103/μL 347 (140–400)
C-reactive protein, mg/dL 100 (<5)
Albumin, g/dL 0.9 (3.5-5.2)
Creatinine, serum (SCr), mg/dL 1.78 (0.51-0.95)
Urea nitrogen, serum (SUN), mg/dL 28 (12.8-42.8)
Creatinine kinase activity, U/L 51 (<170)
Bilirubin, mg/dL <0.08 (<0.9)
GOT, U/L 20 (10–35)
Calcium, mmol/L 1.9 (2.15-2.5)
Ionized calcium, mmol/L 1.22 (1.15-1.29)
Phosphate, mmol/L 1.6 (0.81-1.45)
INR 1.14 (0.85-1.15)
PTT, s 55 (25.9-36.6)
Protein C functional, % 73 (70–134)
Protein S functional, % 73 (60–130)
Lupus anticoagulant 1.04 (1.09-1.34)
Immunofixation Monoclonal gammopathy
IgG-lamba
PTH, pg/mL 78 (15–65)
TSH, μU/mL 9.47 (0.27–4.20)
T3, pmol/L 2.04 (3.4–6.8)
T4, pmol/L 14.4 (10.6-22.7)
Glucose, mg/dL Minimum 50 (60–140 mg/dL)
Insulin, pmol/L 20 (18–173)
Vitamin D, ng/mL <3.00 (20–70)
VEGF, pg/mL 1.329 ± 80 (382 ± 212)
CH50, E/mL 36 (20–50)
C3, g/L 0.91 (0.90-1.80)
C4, g/L 0.62 (0.10-0.40)
C3d, mg/L 7.8 (<9)
Rheumatoid factor, IE/mL <10 (<16)
Antinuclear antibodies negative (negative)
ANCA negative (negative)
Cryoglobulins negative (negative)
Phospholipid antibodies, U/mL 1 (<14)
Protein/ creatinine (urine), g/g 19.9 (<0.15)
Cerebrospinal fluid protein, mg/L 112 (<450)
Cerebrospinal fluid cell count, U/μL 3 (<5)
Cerebrospinal fluid lactate, mmol/L 1.29 (1.5-2.1)
Note: Conversion factors for units: Bilirubin in mg/dL to μmol/l, × 17.1; SCr in
mg/dL to μmol/l, × 88.4; SUN in mg/dL to mmol/l, × 0.357, Glucose in mg/dL
to mmol/l, × 0.05551, Vitamin D in ng/mL to nmol/L, × 2.496.
Figure 2 MRI findings. MRI images revealed abnormalities of the
basal ganglia in our patient. (A) T1-weighted image, showing fine
calcifications in the basal ganglia region. (B) T2-weighted image,
showing regional enhancement. (C) MR spectroscopy did not detect
lactate in the putamen.
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with proximal muscle weakness and elevated creatinine
kinase activity. Muscle biopsy usually shows calcium de-
posits in vessel walls and muscle atrophy [3]. Similarly,
our patient had type II fiber atrophy on muscle biopsy
and polyphasic action potentials on EMG. However, her
normal creatinine kinase activity argues against an active
myopathy in our patient.
Additionally, calciphylaxis may have been etiologic
for the encephalopathy and strio-pallido-dentate calci-
nosis in our patient. Neuropsychiatric diseases are a
typical clinical presentation in patients with strio-pallido-
dentate calcinosis, which is most frequently caused by
disorders of calcium metabolism in adults [4]. Calcifica-
tion of the basal ganglia in calciphylaxis has only been re-
ported once on autopsy. Interestingly, this patient also
had FSGS [3].
To our knowledge, this is the first report of a patient
with POEMS syndrome, calciphylaxis and primary FSGS.
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http://www.biomedcentral.com/1471-2377/14/210Several case reports have proposed an association be-
tween calciphylaxis and POEMS syndrome [1,5,6], and
calciphylaxis has been described in patients with FSGS
[3,7]. Moreover, FSGS is related to multiple myeloma
and treatment of the underlying plasma cell proliferative
disorder improved FSGS, although POEMS syndrome
was not mentioned in that report [8]. Nephrotic syn-
drome, typical of primary FSGS, was not observed in 52
Japanese patients with POEMS syndrome and renal
pathology [9]. Serial renal biopsies of a patient with
POEMS syndrome and recurrent acute renal failure ini-
tially showed thrombotic microangiopathy-like lesions,
followed sequentially by membranoproliferative-like
features and glomerulosclerosis [10]. Consistent with
secondary FSGS, glomerulosclerosis developed after
preceding renal injury, when proteinuria was mild. Our
patient had features typical of primary FSGS, including
nephrotic range proteinuria and renal biopsy findings
with an almost complete podocyte foot process fusion on
electron microscopy. To our knowledge, this is the first
report of a patient with both POEMS syndrome and pri-
mary FSGS.
VEGF may constitute a common pathogenetic link
among POEMS syndrome, calciphylaxis and primary
FSGS. Elevated serum VEGF levels are one of the major
criteria for the diagnosis of POEMS syndrome [2]. VEGF
is essential for both physiological and pathological angio-
genesis and is induced by hypoxia [11]. Proliferating endo-
thelial cells and plasma cells produce VEGF [12]. In the
kidney, VEGF is secreted by podocytes and is crucial for
the maintenance of the glomerular endothelium [13]. The
tyrosine kinase VEGFR-2 is regarded as the main receptor
for VEGF. VEGFR-2 can be blocked by the tyrosine
kinase-inhibitor sunitinib, delaying tumor angiogenesis.
Plasma VEGF concentrations may be elevated in patients
treated with sunitinib [14]. Immunohistochemical staining
of a renal biopsy specimen from a patient developing
FSGS under treatment with sunitinib revealed that VEGF
was markedly positive in his podocytes and renal dysfunc-
tion was dose-dependent [15]. Moreover, children with
primary nephrotic syndrome had higher plasma VEGF
levels during the active nephrotic phase than during re-
mission [16]. Thus, VEGF has been indirectly implicated
in the pathology of FSGS, as well as to promote calcifica-
tion, together with bone morphogenetic proteins, in vas-
cular smooth muscle cells. Thus, VEGF may contribute to
the development of calciphylaxis [1].
To conclude, we report the first case of a patient with
POEMS syndrome, calciphylaxis and primary FSGS. Be-
cause the association of these three conditions may be
coincidental, further studies are needed to prove this as-
sociation. VEGF may be a common pathogenetic factor,
suggesting that treatment with antiangiogenic agents may
improve patient outcomes.Consent
Written informed consent was obtained from the guard-
ian of our patient for publication of this case report and
the accompanying images. A copy of the written consent
is available for review by the Editor of this journal.
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